高级检索
当前位置: 首页 > 详情页

Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Jiao Tong Univ, Sch Med,Hongqiao Int Inst Med,Chinese Minist Educ, Shanghai Tongren Hosp,Chem Biol Div,Fac Basic Med, Shanghai Univ E Inst,Key Lab Cell Differentiat &, Shanghai 200025, Peoples R China [2]Shanghai Jiao Tong Univ, Sch Med, Shanghai Ninth Pevoples Hosp, Dept Transfus Med, Shanghai 200011, Peoples R China [3]Inner Mongolia Med Univ, Ordos Clin Coll, Oldos City Cent Hosp, Inner Mongolia Auton Reg, Hohhot 017000, Peoples R China [4]Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp Affiliated,State Key Lab Med Gen, Shanghai Inst Hematol,Natl Res Ctr Translat Med, Shanghai 200025, Peoples R China [5]State Key Lab Bioorgan & Nat Prod Chem, Shanghai, Peoples R China
出处:
ISSN:

关键词: Deubiquitinating enzyme Ubiquitination Ubiquitin-specific Protease 9x SRY-Related HMG-Box gene 2

摘要:
SOX2 has been viewed as a critical oncoprotein in osteosarcoma. Emerging evidence show that inducing the degradation of transcription factors such as SOX2 is a promising strategy to make them druggable. Here, we show that neogambogic acid (NGA), an active ingredient in garcinia, significantly inhibited the proliferation of osteosarcoma cells with ubiquitin proteasome-mediated degradation of SOX2 in vitro and in vivo. We further identified USP9x as a bona fide deubiquitinase for SOX2 and NGA directly interacts with USP9x in cells. Moreover, knockdown of USP9x inhibited the proliferation and colony formation of osteosarcoma cells, which could be rescued by overexpression of SOX2. Consistent with this, knockdown of USP9x inhibited the proliferation of osteosarcoma cells in a xenograft mouse model. Collectively, we identify USP9x as the first deubiquitinating enzyme for controlling the stability of SOX2 and USP9x is a direct target for NGA. We propose that targeting the USP9x/SOX2 axis represents a novel strategy for the therapeutic of osteosarcoma and other SOX2 related cancers.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2025]版:
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Shanghai Jiao Tong Univ, Sch Med,Hongqiao Int Inst Med,Chinese Minist Educ, Shanghai Tongren Hosp,Chem Biol Div,Fac Basic Med, Shanghai Univ E Inst,Key Lab Cell Differentiat &, Shanghai 200025, Peoples R China [2]Shanghai Jiao Tong Univ, Sch Med, Shanghai Ninth Pevoples Hosp, Dept Transfus Med, Shanghai 200011, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:23410 今日访问量:0 总访问量:1276 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)